Target intelligence / Profile preview

CCA tRNA nucleotidyltransferase 1, mitochondrial (TRNT1)

Target
TRNT1
Molecular classification
Enzyme, Nucleotidyltransferase, Mitochondrial protein
01

Overview

CCA tRNA nucleotidyltransferase 1, mitochondrial (TRNT1) is an essential nucleotidyltransferase enzyme that catalyzes the addition and repair of the conserved CCA sequence at the 3' end of tRNA molecules, a modification required for tRNA aminoacylation and subsequent protein translation. It is a mitochondrial enzyme encoded by the nuclear genome, playing a central role in both tRNA maturation and tRNA quality control by distinguishing stable tRNAs (adding CCA) from unstable or defective tRNAs (adding CCACCA, leading to degradation). Mutations in TRNT1 cause inherited diseases such as sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, highlighting its crucial role in cellular and mitochondrial function[1][2][4][7]. No approved drugs directly target TRNT1, reflecting its essential housekeeping role and the likely toxicity of its inhibition.

Other names
tRNA nucleotidyltransferase 1TRNA Nucleotidyl Transferase 1CCA1MtCCACGI-47SIFDATP(CTP):tRNA nucleotidyltransferaseCCA tRNA nucleotidyltransferase 1, mitochondrialtRNA CCA Nucleotidyl Transferase 1mt tRNA CCA-Pyrophosphorylase
02

Mechanism of action

Drugs targeting this enzyme would theoretically inhibit or modify the CCA-adding function, interfering with tRNA maturation and mitochondrial protein synthesis (no therapeutic drugs currently known)

03

Biological functions

Addition of CCA to tRNA 3' endtRNA maturation and processingtRNA quality control and repairtRNA surveillance (identifying and targeting unstable tRNAs for degradation)RNA binding
04

Disease associations

Sideroblastic anemia with B-cell immunodeficiencyPeriodic feversDevelopmental delayRetinitis pigmentosa and erythrocytic microcytosis
05

Safety considerations

Essential for mitochondrial translation and cell viability; inhibition could cause severe systemic mitochondrial dysfunction, anemia, and immunodeficiency.
06

Biomarkers

TRNT1 mutation analysis (for diagnosis of SIFD and related syndromes)

Beyond the preview

Go deeper on CCA tRNA nucleotidyltransferase 1, mitochondrial (TRNT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCA tRNA nucleotidyltransferase 1, mitochondrial (TRNT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call